Monte Rosa Therapeutics Inc Total Liabilities
Monte Rosa Therapeutics Inc total liabilities. Based on the latest financial reports, Monte Rosa Therapeutics Inc (GLUE) has total liabilities worth $211.03 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Monte Rosa Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Monte Rosa Therapeutics Inc (2019–2025)
Total liabilities of Monte Rosa Therapeutics Inc from 2019 to 2025. This chart illustrates how Monte Rosa Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Monte Rosa Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Monte Rosa Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Time Technoplast Limited
NSE:TIMETECHNO
|
India | Rs-41.66 Billion |
|
GuoChuang Software Co Ltd
SHE:300520
|
China | CN¥1.89 Billion |
|
CeriBell, Inc
NASDAQ:CBLL
|
USA | $38.03 Million |
|
Jupiter Wagons Limited
NSE:JWL
|
India | Rs17.26 Billion |
|
Fujian Longxi Bearing Group Co Ltd
SHG:600592
|
China | CN¥897.22 Million |
|
Ampoc Far-East Co Ltd
TW:2493
|
Taiwan | NT$2.15 Billion |
|
Hunan Corun New Energy Co Ltd
SHG:600478
|
China | CN¥7.30 Billion |
|
Corticeira Amorim
LS:COR
|
Portugal | €491.25 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Monte Rosa Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Monte Rosa Therapeutics Inc balance sheet assets.
Liquidity & Leverage Metrics
Monte Rosa Therapeutics Inc Total Liabilities Ratios Explained
Monte Rosa Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Monte Rosa Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Monte Rosa Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Monte Rosa Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $215.60 Million | -0.09% |
| 2024-12-31 | $215.80 Million | +73.32% |
| 2023-12-31 | $124.50 Million | +75.42% |
| 2022-12-31 | $70.98 Million | +277.25% |
| 2021-12-31 | $18.81 Million | -80.82% |
| 2020-12-31 | $98.11 Million | +322.11% |
| 2019-12-31 | $23.24 Million | -- |
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment… Read more